Full List Of Stories
FTSE 250 movers: Travel issues drag on second-tier index, Cineworld gains
Travel-related issues were at the bottom of the pile on the second-tier index on Monday, as governments around the world, including the US and UK, moved to tighten restrictions on foreigners arriving from virus hot spots.
Reckitt Benckiser withdraws $1.4bn claim against Indivior
Indivior has reached a settlement with Reckitt Benckiser regarding the latter's claims against derived from its 2019 settlement with the US Department of Justice and Federal Trade Commission.
Tuesday preview: UK employment, Distributive Trades Index in focus
Financial markets' focus on Tuesday will be on the latest UK employment.
Sector movers: Concerns around Covid vaccine rollouts drag on sentiment
News of setbacks for the expected pace of Covid-19 vaccinations, particularly on the Continent, but also further afield, potentially including in the likes of Australia, Canada and Thailand weighed on investor sentiment.
Europe close: Value stocks fall back amid bad news for Covvid-19 vaccine rollouts
European shares fell back at the start of the week with investors scurrying back towards tech stocks as the prospect of extended Covid lockdowns on the Continent battered travel and leisure companies.
Italian PM Conte set to step down on Tuesday
Italy's Prime Minister is set to step down on Tuesday.
Blackberry unaware of reasons behind surge in company's share price
Blackberry said it was not aware of any "material, undisclosed corporate developments" that might explain Monday's rapid climb in its stock price.
Johnson and Johnson Covid-19 vaccine may approved in two weeks
Johnson&Johnson's Covid-19 vaccine may be two weeks from approval, one of the top US health officials said.
'Herd immunity' against Covid-19 possible in US by spring, some analysts believe
The number of new Covid-19 infections in the States continued to slow at the weekend, falling below the levels seen in late November.
AstraZeneca will fail to meet Covid-19 vaccine delivery targets in Europe
AstraZeneca will fail to deliver the number of Covid-19 vaccine doses which it had committed to with the European Union for the first quarter.
Merck to refocus efforts on developing Covid-19 therapies
Merck&Co. will close its Covid-19 vaccine development programme after clinical trial results came up short.